Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
about
Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell ReplacementBiologics in organ transplantationTargeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificitySuccessful Combined Pancreas Fourth-Kidney Third and Pancreas Third-Kidney Second Transplantation: A Case Report.Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years.Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantationSingle dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.Developments in clinical islet, liver thoracic, kidney and pancreas transplantation in the last 5 years.The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.Minimization of steroids in kidney transplantation.Steroid elimination-who, when, how?Validation of the BETA-2 Score: An Improved Tool to Estimate Beta Cell Function After Clinical Islet Transplantation Using a Single Fasting Blood Sample.Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.Cost-effective immunosuppressive options for solid organ transplantation: a guide to lower cost for the renal transplant recipient in the USA.Induction therapy in pancreas transplantation.Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective.Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions.Transplantation: current developments and future directions.Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients.A retrospective study to describe the epidemiology and outcomes of opportunistic infections after abdominal organ transplantation.Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.B-cell tolerance in transplantation: is repertoire remodeling the answer?Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.Comparison of recipient outcomes following transplant from local versus imported pancreas donors.Use of mTOR inhibitors in human organ transplantation.Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.Alemtuzumab induction in simultaneous pancreas and kidney transplantation.Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery.CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody
P2860
Q26769878-FE7F192C-A3B6-416A-8DA7-8020666DD4ABQ26829578-59342D69-F818-41A3-9DB0-C28FCE1A8370Q33415472-1C132295-F238-44C9-9E2E-6539226EADFBQ33434425-918B4A88-D3BA-4965-8B9D-AE2F90690A03Q35776408-3A363EF8-C20F-47EA-BBAC-41940BC20BC2Q35881889-1049AD6A-4DDA-4A49-B5E5-A36B7B1A4DCDQ35963432-198F62D9-1CA6-4283-B12B-7CD10E9CC9D1Q36505718-73484461-443D-419F-8B33-B957BA6FC53EQ36570565-4559FA4A-D5DA-475D-B82D-2829ABF44475Q36906347-7797CF21-7706-4D77-BAB9-D5E52A75D6E6Q37097694-163FF733-2F72-46DC-8CC1-D68F309E7F15Q37228814-38FCCFBB-7A1D-4E23-ABC7-36AE3EA37585Q37356120-FE4A83F8-2919-4258-B885-28452CE5BE68Q37357372-5C7AA9EC-9DDF-4560-9037-8A6823F97691Q37810958-6913C575-B471-4196-B46E-3C483A4466F5Q37810962-1977FC60-D275-448B-86B4-C4A82E1F923FQ38106742-E04AEB2C-3D21-413C-8B79-E3D55633FCB3Q38162892-345CEE11-A24F-4819-ADE7-C3544936C50AQ38254279-3EFA7BB1-3420-45E7-AB0A-8DCAA3F60392Q39900432-7D01876E-5AFF-437B-95C5-C3B8A317D08BQ40159236-F7AC7642-8FB9-4304-A9BA-E45F0F16546DQ40270917-479E30A6-FAD2-48C5-BE03-C564E0549C4DQ40302250-1514B50E-800E-4988-A446-9148F8095B5BQ40956691-BC97276A-A7AF-4655-8AA8-21CDABBAF66FQ42038591-81168528-7ACB-4012-B9B5-2E9789A223C6Q42502255-EBE0DDC8-2C89-4C18-B0E0-9C2D6871DA60Q42624234-E2E57786-680F-4D36-BBED-198B0C8ECB11Q43061556-88A312B8-D30D-49DD-A092-AD885CC50713Q44433786-1681BEB6-6F4E-4896-9A29-DDF2C3935CC6Q44701983-9E1B62AB-E8FF-4A0F-A8F0-1685C0773D0FQ46738187-7812E638-0BB6-4F63-A778-4D9AFA51F9DAQ46763767-845105FF-56D1-4BFE-828B-C342E9052E59Q46793006-09485171-2333-42E5-8064-37A11C8492D0Q53595595-4B2A20BD-A720-4F2B-AA6A-25B42399ADC4Q59230712-0E0323FA-0AB0-4A28-8B07-F58801AAB944
P2860
Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Alemtuzumab induction and pred ...... induction - long-term results.
@en
Alemtuzumab induction and pred ...... induction - long-term results.
@nl
type
label
Alemtuzumab induction and pred ...... induction - long-term results.
@en
Alemtuzumab induction and pred ...... induction - long-term results.
@nl
prefLabel
Alemtuzumab induction and pred ...... induction - long-term results.
@en
Alemtuzumab induction and pred ...... induction - long-term results.
@nl
P2093
P2860
P1476
Alemtuzumab induction and pred ...... induction - long-term results.
@en
P2093
D B Kaufman
J R Leventhal
L G Gallon
M A Parker
P2860
P304
P356
10.1111/J.1600-6143.2005.01166.X
P407
P577
2006-02-01T00:00:00Z